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Homozygous deletions of p16/CDKN2A are prev-
alent in cancer, and these mutations commonly
involve co-deletion of adjacent genes, including
methylthioadenosine phosphorylase (MTAP). Here,
we used shRNA screening and identified the meta-
bolic enzyme, methionine adenosyltransferase II
alpha (MAT2A), and the arginine methyltransferase,
PRMT5, as vulnerable enzymes in cells with MTAP
deletion. Metabolomic and biochemical studies
revealed a mechanistic basis for this synthetic
lethality. The MTAP substrate methylthioadenosine
(MTA) accumulates upon MTAP loss. Biochemical
profiling of a methyltransferase enzyme panel re-
vealed that MTA is a potent and selective inhib-
itor of PRMT5. MTAP-deleted cells have reduced
PRMT5 methylation activity and increased sensi-
tivity to PRMT5 depletion. MAT2A produces the
PRMT5 substrate S-adenosylmethionine (SAM),
and MAT2A depletion reduces growth and PRMT5
methylation activity selectively in MTAP-deleted
cells. Furthermore, this vulnerability extends to
PRMT5 co-complex proteins such as RIOK1. Thus,
the unique biochemical features of PRMT5 create
an axis of targets vulnerable in CDKN2A/MTAP-
deleted cancers.INTRODUCTION
Loss-of-function mutations in tumor suppressor genes are
critical in the molecular pathogenesis of cancer, yet few ther-
apies selectively target cancers based on loss-of-function mu-
tations in tumor suppressors (Lord et al., 2015). This discord
can be explained by the simple observation that the mutant
protein cannot be directly inhibited for therapeutic benefit.
Tumor suppressors that are inactivated by homozygous dele-
tion are most problematic for targeted therapy, because the574 Cell Reports 15, 574–587, April 19, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://lack of residual protein obviates therapeutic strategies that
would directly activate, stabilize, or repair the defective tumor
suppressor.
The chromosome 9p21 (chr9p21) locus is homozygously
deleted in approximately 15% of all human cancers (Beroukhim
et al., 2010), ranging in frequency up to >50% in glioblastoma
multiforme (Parsons et al., 2008). The chr9p21 locus includes
the CDKN2A gene, which encodes critical tumor suppressors
p19-ARF and p16-INK4a (Figure 1A) (Kamijo et al., 1997;
Serrano et al., 1993). Although chr9p21 deletion was first
discovered more than 30 years ago (Chilcote et al., 1985),
molecularly targeted therapies for CDKN2A loss have proven
elusive, and it may be necessary to identify alternative ap-
proaches to target tumors with deletion of chr9p21. The
chr9p21 deletions frequently involve co-deletion of genes prox-
imal to CDKN2A. Foremost among these is the methylthioade-
nosine phosphorylase (MTAP) gene, which resides within 100
kb of CDKN2A (Figure 1A), and homozygous co-deletion of
MTAP occurs in 80%–90% of tumors with CDKN2A deletion
(Zhang et al., 1996). MTAP is a critical enzyme in the methionine
salvage pathway that metabolizes the byproduct of polyamine
synthesis, 50-methylthioadenosine (MTA), leading to the even-
tual regeneration of methionine and adenine (Zappia et al.,
1988). Elaboration of MTAP-selective anti-cancer targets re-
mains an intriguing and unsolved scientific question (Muller
et al., 2015). MTAP deletion has been reported to create sensi-
tivity to inhibitors of purine biosynthesis (Li et al., 2004), although
this metabolic vulnerability is lost in vivo, as tumors uptake
circulating adenine and escape the purine biosynthesis sensi-
tivity (Ruefli-Brasse et al., 2011). Despite the limited success
to date in selectively targeting MTAP-deficient cancers, deletion
of other metabolic genes has been shown to create targetable
vulnerabilities (Frezza et al., 2011; Muller et al., 2012); thus, we
sought to identify collateral vulnerabilities in MTAP-deficient
cells.
To identify vulnerabilities that arise uponMTAP loss in cancer,
we employed small hairpin RNA (shRNA) depletion screening in
an isogenic cancer cell line pair that varies only inMTAP status.
AlthoughMTAP encodes a metabolic enzyme, we hypothesized
that MTAP loss may create collateral vulnerabilities in bio-
logic pathways that extend beyond metabolism. To test thecreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Functional Genomics Screening Identifies Genes that Are Synthetic Lethal with MTAP Loss
(A) Schematic depicting the chr9 and chr9p21.3 region containing the MTAP gene close to the CDKN2A gene and its two coding sequences, p16/INK4A and
p19/ARF.
(B) Schematic depicting the shRNA depletion screen in the colon carcinoma HCT116 MTAPwt and MTAP/ isogenic cell line pair.
(C) Immunoblot analysis demonstrating a lack of MTAP protein expression in HCT116 MTAP/ cells.
(D) Gene scores in HCT116 MTAP/ versus MTAPwt cells.
(E) Top genes that scored as differentially depleted in HCT116 MTAP/ cells. Genes pursued in subsequent studies are highlighted in green (MAT2A), red
(PRMT5), and magenta (RIOK1).
(F) Changes in the abundance of the individual MAT2A, PRMT5, and RIOK1 shRNAs in HCT116MTAP/ versusMTAPwt cells in the screen. Individual shRNAs
are highlighted in green (MAT2A), red (PRMT5), or magenta (RIOK1). The rest of the shRNAs in the library are shown as gray diamonds.hypothesis that MTAP deletion would create collateral vulnera-
bilities in metabolic and non-metabolic pathways, we used a
novel shRNA library consisting of shRNA hairpins targeting
the 3,000+ genes of the metabolome, as well as an additional
3,000+ non-metabolic genes.
Through this screen and subsequent investigation, we identi-
fied an axis of targets that becomes vulnerable upon MTAP
loss in cancer. Central in this axis is protein arginine methyl-
transferase 5 (PRMT5). Using metabolomic and biochemical ap-
proaches, we discovered that MTA, the substrate of the MTAP
enzyme reaction, accumulates dramatically in MTAP-deleted
cancers. MTA inhibits PRMT5 enzyme activity and leads to
reduced basal PRMT5 methylation in MTAP-deleted cancers.
This vulnerability extends both upstream and downstream of
PRMT5. We show that the metabolic enzymemethionine adeno-
syltransferase II alpha (MAT2A), which produces PRMT5 sub-
strate S-adenosylmethionine (SAM), is also selectively essential
inMTAP-deleted cancers, as are multiple different PRMT5 bind-
ing partners, including the kinase RIOK1.RESULTS
shRNA Depletion Screen in the HCT116 MTAPwt/
MTAP/ Isogenic Pair
To identify genes for which loss of function would lead to selec-
tive killing of MTAP-deficient cells, we performed an shRNA-
based depletion screen in the HCT116 colon carcinoma cell
line and an isogenic clone of HCT116 cells that had been genet-
ically modified to delete exon 6 of the MTAP gene (Figure 1B),
which led to complete loss of MTAP protein expression (Fig-
ure 1C). To provide broad coverage for potential synthetic lethal
interactions, we constructed a library that encompassed the
complete metabolome (3,067 genes), the mitochondrial prote-
ome (Pagliarini et al., 2008), the epigenome (Arrowsmith et al.,
2012), the kinome (http://www.uniprot.org/), and >1,500 addi-
tional genes representing diverse biologic pathways. HCT116
MTAP/ and MTAP wild-type (WT) cells were transduced with
the shRNA library containing eight shRNAs per gene, and the
pool of knockdown cells was passaged for 12 cell divisions. AtCell Reports 15, 574–587, April 19, 2016 575
the end of the culture, we measured the relative abundance of
each shRNA barcode via deep sequencing and calculated the
fold depletion of each shRNA compared to the untransduced
library DNA. After normalization, we then calculated an MTAP
selectivity score for each gene based on the difference in the
log2 fold change in the abundance of each of the eight shRNAs
targeting the gene inMTAP/ versusMTAPwt cells (Figure 1D).
This analysis demonstrated that although most genes, as well
as shRNA controls, had a similar score in both MTAP/ and
MTAPwt cells (Figure 1D), a subset of genes was selectively
depleted in MTAP/ cells (Figures 1D–1F and S1A–S1C;
Table S1). The top hit in the screen was MAT2A (Figures 1D
and 1E). MAT2A catalyzes the synthesis of the universal biologic
donor of methyl groups, SAM, via adenosylation of methionine.
Six of eight (75%)MAT2A-targeting hairpins displayed markedly
increased depletion in theMTAP/ cells compared toMTAPwt
cells (Figures 1F and S1A). The remaining two hairpins displayed
little depletion in either cell line, perhaps due to ineffective
knockdown of the target. The second-best scoring gene in the
screen was PRMT5, which is the catalytic subunit of a multipro-
tein methyltransferase complex that includes PRMT5 in com-
plex with obligate binding partner WD45/MEP50 (WD repeat
domain 45/methylosome protein 50), and other scaffolding pro-
teins (Figures 1D–1F and S1B) (Meister et al., 2001; Pesiridis
et al., 2009). PRMT5 belongs to the type II PRMT subfamily
of arginine methyltransferases and catalyzes the formation of
symmetric di-methylarginines (SDMAs) in target proteins, using
MAT2A product SAM. The eleventh-highest-scoring gene,
RIOK1, encodes a Rio domain-containing protein, which is a
binding partner of PRMT5 that directs PRMT5 toward selective
methylation of a subset of PRMT5 substrates (Figures 1D–1F
and S1C) (Guderian et al., 2011). These data suggest that
MAT2A-, PRMT5-, and RIOK1-catalyzed reactions are critical
for maintaining viability of MTAP-deficient cells. Although all
three highlighted hits represent therapeutically and biologically
interesting targets, we first tested whether MAT2A, the top hit
in our shRNA screen, represents a bona fide synthetic lethal
target in MTAP-deficient cells.
MAT2A Is Selectively Essential in MTAP-Deficient Cells
We used the HCT116 isogenic pair and created cell lines stably
expressing non-targeting (NT) shRNA and MAT2A-targeting
shRNA, as well as cell lines that were additionally reconsti-
tuted with shRNA-resistant MAT2A cDNA or that expressed
MTAP cDNA. We confirmed efficient MAT2A knockdown and
MAT2A and MTAP re-expression in HCT116 cells by western
blot (Figure 2A). We also confirmed that MAT2A knockdown
resulted in reduced cellular levels of SAM in both HCT116
genotypes using liquid chromatography-mass spectrometry
(LC-MS) analysis (Figure 2B). We then tested the impact of
MAT2A knockdown in MTAPwt versus MTAP/ cells in a
6-day in vitro growth assay (Figure 2C). The results were in
agreement with our genomic screen. MAT2A knockdown selec-
tively attenuated growth of MTAP/ but not WT cells (Fig-
ure 2C). This growth defect was rescued by introduction of
a shRNA-resistant MAT2A cDNA construct, indicating the on-
target effect of the shRNA, and was partially rescued by
MTAP re-expression (Figure 2C).576 Cell Reports 15, 574–587, April 19, 2016To investigate the in vitro-to-in vivo translation of our findings,
we conducted xenograft efficacy studies with HCT116 isogenic
cell lines expressing inducible MAT2A shRNA (shMAT2A). In
these studies, tumors were allowed to form before treatment of
animals with doxycycline (DOX) to assess the role of MAT2A in
the proliferation of established tumors. Efficiency of MAT2A
knockdown in vivo was confirmed by western blot (Figure S2A).
We confirmed that MAT2A genetic ablation in vivo resulted in
a similar reduction in SAM levels in HCT116 xenografts of
both genotypes (Figure S2B). In accordance with our findings
in vitro, MTAP-selective tumor growth reduction was observed
in vivo upon MAT2A depletion by shRNA (Figure 2D). To demon-
strate that this selective growth reduction was an on-target
effect, we performed an expanded in vivo study with a WT
MAT2A cDNA rescue of shMAT2A. This experiment confirmed
the efficacy observed in our first in vivo study, and as with the
in vitro studies, growth inhibition was rescued in the xenografts
expressing a MAT2A cDNA (Figures S2C and S2D).
We next sought to assess sensitivity to MAT2A ablation in a
cancer model that possesses an endogenous deletion at the
MTAP/CDKN2A locus. Thus, we generated breast carcinoma
MCF7 cell lines stably expressing NT shRNA andMAT2A-target-
ing shRNA, as well as cell lines that were additionally reconsti-
tuted with shRNA-resistant MAT2A cDNA. We demonstrated
efficiency of MAT2A knockdown and re-expression by western
blot (Figure 2E). Consistent with observations made in the
HCT116 model system, MAT2A knockdown attenuated growth
of MTAP-deleted MCF7 cells measured in a 7-day growth assay,
whileMAT2A cDNA reconstitution resulted in complete rescue of
the growth phenotype (Figure 2F). We then tested MAT2A target
dependence in vivo in an orthotopic MCF7 model and observed
a robust reduction in MCF7 tumor growth upon MAT2A knock-
down, which was fully reverted by expression of WT MAT2A
cDNA (Figure 2G). Western blot confirmed reduction in MAT2A
levels upon DOX treatment and maintenance of MAT2A expres-
sion in tumors expressing the MAT2A cDNA rescue construct
(Figure 2H). In addition, MAT2A genetic ablation in MCF7 tumors
in vivo resulted in reduction in SAM levels, which was rescued by
the MAT2A cDNA (Figure S2E).
Although the MCF7 model indicates that the MAT2A vulner-
ability extends beyond the genetically engineered HCT116
MTAP/ setting, we sought to test further the MTAP selectivity
of MAT2A dependence by performing shRNA studies in a panel
of seven additional cell lines that vary in deletion status at the
endogenous CDKN2A/MTAP locus. MAT2A knockdown led to
greater growth inhibition in the CDKN2A/MTAP-deleted cells
(Figure 2I). MAT2A knockdown was comparable across the cell
line panel, irrespective of CDKN2A/MTAP deletion status (Fig-
ure S2F). Thus, the selective vulnerability that we identified in
our HCT116model system screen persists in tumors with endog-
enous deletion of the CDKN2A/MTAP locus.
MTAP Deficiency Creates an Altered Metabolic State
To better understand the connection between MTAP deficiency
and MAT2A function in cells, we next investigated metabolic
changes that occur upon MTAP loss. Both MTAP and MAT2A
participate in the reactions of the methionine pathway (Fig-
ure 3A). MAT2A generates SAM, the universal biologic donor
Figure 2. MAT2A Is Selectively Essential in HCT116 MTAP/ Cells
(A) Immunoblot analysis of the indicated proteins in HCT116 MTAP/ and MTAPwt cells stably expressing NT shRNA (shNT), shMAT2A, shRNA-resistant
MAT2Awt cDNA (shMAT2A+resc), or shMAT2A and MTAP cDNA (shMAT2A+MTAP). DOX (200 ng/ml) was added to induce shRNA expression.
(B) SAM levels as determined by targeted LC-MS analysis in the HCT116 isogenic pair expressing inducible shNT or shMAT2A (mean ± SD, n = 3). All cells were
treated with DOX.
(legend continued on next page)
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of methyl groups, from ATP and methionine. MTAP con-
verts MTA, a byproduct of polyamine biosynthesis, back to
methionine and adenine in the methionine salvage pathway (Fig-
ure 3A). Because MTAP is the only enzyme in mammalian cells
known to catalyze the degradation of MTA, we hypothesized
that MTAP deficiency would result in accumulation of MTA and
blockade of the methionine salvage pathway. We first tested
this hypothesis in the context of a broad, untargeted LC-
MS-based metabolomic assessment of intracellular metabolite
levels in the HCT116 MTAP isogenic pair (Figure 3B). This anal-
ysis revealed that, among 237 annotated metabolites that were
detected, MTA displayed the largest abundance increase in
MTAP/ cells compared to HCT116 parental control (Figure 3B,
left panel). Decarboxylated S-adenosylmethionine (dcSAM), the
metabolite upstream from MTA in the polyamine biosynthetic
pathway, displayed the second-largest increase. The enrich-
ment of these two metabolites in MTAP/ cells was highly sta-
tistically significant (Figure 3B, right panel). Elevation of MTAwas
confirmed using absolute quantitation with targeted LC-MS
analysis in the HCT116 isogenic pair (Figure 3C). A screen of a
large cancer cell line panel comprising 249 cell lines of diverse
tissue origin demonstrated consistent accumulation of MTA in
the media of cells with endogenous MTAP deletion (Figure 3D),
suggesting thatMTAP/ HCT116 cancer cells faithfully recapit-
ulate the metabolic phenotype of CDKN2A/MTAP-deleted cells.
MTA Inhibits PRMT5 Activity In Vitro and In Vivo
MTA and structurally related analogs have been reported to
inhibit a protein methyltransferase activity partially purified
from chick embryos, albeit with an inhibitor constant (Ki) of
400 mM, indicating very low potency of inhibition (Enouf et al.,
1979). We hypothesized that MTA might more potently and
selectively inhibit specific methyltransferases, such as PRMT5.
To test this hypothesis, we performed an in vitro biochemical
screen assessing activity of 33 different N-methyltransferases
following treatment with 10 and 100 mM MTA. Inhibition by
MTAwas only observed in a small subset of the panel, and stron-
gest inhibition was observed for PRMT5 and PRMT4, members
of the argininemethyltransferase family (Figure 4A). Furthermore,
PRMT5 demonstrated high sensitivity to MTA in subsequent ex-
periments testing a range of MTA concentrations (Figure 4B).
Next, we analyzed theMTA Ki for PRMT5, PRMT4, and a diverse
subset of methyltransferases (Figure 4C; Table S4). Strikingly,(C) MAT2A is selectively essential in HCT116MTAP/ cells in vitro. Percent grow
with or withoutMAT2A orMTAP rescue, versus no knockdown (DOX) control m
calculated using a two-tailed paired t test.
(D) Kinetics of tumor growth upon in vivo ablation of MAT2A in subcutaneous xeno
once tumors reached 200–300 mm3 in diameter (mean ± SEM, n = 5–6).
(E) Immunoblot analysis of the indicated proteins in MCF7 cells stably expressing
was induced.
(F) MAT2A is essential in MCF7 cells in vitro. Percent growth of MCF7 cells u
knockdown (DOX) control measured in a 7-day in vitro growth assay (mean ± S
(G) Kinetics of tumor growth upon in vivo ablation of MAT2A in orthotopic MCF7
diameter (mean ± SEM, n = 9–10).
(H) Immunoblot analysis of the indicated proteins in tumors formed fromMCF7 cel
to the mouse chow to induce shMAT2A expression.
(I) Cell lines were stably transduced with shMAT2A or control shRNA (shNT or Lu
in vitro growth assay (mean ± SD, n = 15).
578 Cell Reports 15, 574–587, April 19, 2016the MTA Ki for PRMT5 (0.26 mM) was >20-fold lower than that
of any other methyltransferase, indicating that PRMT5 is far
more sensitive to inhibition by MTA than any other methyltrans-
ferase tested. This biochemical observation is consistent with
our shRNA screening data demonstrating that PRMT5 was the
strongest MTAP/ selective hit among all methyltransferases
in the library (Figure 1D; Table S1).
We next assessed whether MTA accumulation in MTAP-defi-
cient cells reduces PRMT5 activity. We performed western blot
analysis of SDMA marks in total cell lysates of a panel of
MTAPwt and MTAP-deleted cell lines, using an antibody that
was generated using symmetric dimethyl histone H4R3 antigen
and detects multiple SDMA marks (Figure 4D). We observed
that MTAP-deleted cell lines consistently demonstrated lower
levels of SDMA marks. Finally, we took advantage of the avail-
ability of a potent, cell permeable transition state analog inhibi-
tor of MTAP (Basu et al., 2011; Longshaw et al., 2010). We
treated HCT116 MTAPwt cells with the MTAP inhibitor for
3 days and measured the impact of pharmacologic inhibition
of MTAP on the levels of SDMA marks (Figure 4E). Treatment
of MTAPwt cells with MTAP inhibitor at doses sufficient to
increase MTA levels to those observed in MTAP/ cells (Fig-
ure S4A) resulted in reduction in the levels of SDMA marks (Fig-
ure 4E) without an impact on cell growth (Figure S4B). The
reduction observed upon pharmacologic inhibition of MTAP
was equivalent to that observed upon genetic deletion of
MTAP. These data strongly indicate that PRMT5 activity is
impaired by MTA in MTAP-deleted cells, resulting in reduced
methylation of its protein substrates. Because PRMT5 was a
top hit in the shRNA screen, we hypothesized that reduced
basal activity of PRMT5 upon MTAP loss creates vulnerability
to additional ablation of PRMT5 activity by shRNA.
PRMT5 Is Selectively Essential in MTAP/ Cells upon
Genetic Ablation
We thus sought to confirm that PRMT5, similarly to MAT2A, rep-
resents abonafide synthetic lethal target inMTAP-deficient cells.
Initially, we performed small interfering RNA (siRNA)-mediated
knockdown of PRMT5 in the HCT116 isogenic pair (Figures
S5AandS5B). Four separatePRMT5-targeting siRNAsdisplayed
a significant growth reduction in HCT116 MTAP/ cells, with
only modest impact on the growth of HCT116 MTAPwt
cells. Furthermore, reconstitution of HCT116 MTAP/ cellsth of HCT116MTAP/ and MTAPwt cells upon MAT2A knockdown (+DOX),
easured in a 6-day in vitro growth assay (mean ± SD, n = 5). The p values were
grafts of shMAT2AHCT116 isogenic pair cell lines. DOX treatment was initiated
shNT, shMAT2A, and shMAT2A+resc. DOX indicates where hairpin expression
pon MAT2A knockdown (+DOX), with or without MAT2A rescue, versus no
D, n = 5). The p values were calculated using a two-tailed paired t test.
tumors. DOX treatment was initiated once tumors reached 200–300 mm3 in
ls stably expressing shMAT2A, with or without MAT2A rescue. DOX was added
c), and impact of MAT2A knockdown on cell growth was measured in a 6-day
Figure 3. MTA Accumulates in MTAP-Deficient Cancers
(A) Schematic of methionine recycling and salvage pathways.
(B) Intracellular metabolite levels analysis using untargeted LC-MS in the
HCT116 isogenic cell line pair. Waterfall plot demonstrates the log2 of mean
fold change (FC) in HCT116 MTAP/ cells compared with MTAPwt control
versusmetabolite identification. Volcano plot of the log2 ofmean FC inHCT116
MTAP/ cells compared with MTAPwt control versus log10 p value for each
metabolite is also shown. MTA and dcSAM are highlighted in red.
(C) Measurement of intracellular MTA levels in HCT116 isogenic cell lines by
targeted LC-MS (mean ± SD, n = 3).
(D) Media MTA levels in a panel of 249 cancer cell lines of various tissues of
origin.withMTAP cDNA resulted in attenuation of the growth phenotype
uponPRMT5 knockdown (Figures S5CandS5D).We next gener-
ated HCT116MTAP/ andMTAPwt cell lines stably expressing
DOX-inducible shRNA targeting PRMT5. We confirmed that
PRMT5 was efficiently knocked down by measuring levels
of PRMT5 protein (Figure 5A). Consistent with our genomic
screening results, PRMT5 knockdown with DOX-inducible
shRNA led to more complete growth reduction inMTAP/ cells
than in MTAPwt cells (Figure 5B). Expression of a small hairpin
PRMT5-resistantPRMT5cDNA inMTAP/cells rescuedgrowth
inhibition upon endogenous PRMT5 knockdown, while expres-sion of catalytically dead R368A PRMT5 mutant (Pollack et al.,
1999) cDNA did not (Figure 5B). Thus, the anti-proliferative effect
of this shRNA is due to PRMT5 depletion, not off-target shRNA
effects. Lack of rescue by R368A mutant PRMT5 indicates that
PRMT5 enzyme activity is essential inMTAP/ cells. These find-
ings provide validation of our screening results and suggest that
PRMT5 catalytic function is critical for maintaining growth of
MTAP-deficient cells. Because PRMT5 activity results in SDMA
residues in numerous cellular proteins, we next assessed the
impact of PRMT5 knockdown on SDMAmarks in our model (Fig-
ure 5C). Aswasobserved in the cell panel analysis (Figure 4D),we
noted thatMTAP/cells have lowerbasal levels ofSDMAmarks,
suggesting impaired basal PRMT5 activity. Furthermore, PRMT5
knockdown led to more complete reduction in levels of SDMA
marks in the MTAP/ cell line, despite equivalent reduction in
the PRMT5 protein level inMTAP/ andWT cells. The reduction
in SDMA marks was rescued by WT PRMT5 but not by R368A
mutant PRMT5 cDNA (Figure 5C). To validate our findings, we
pre-treated HCT116 MTAPwt cells stably expressing DOX-
inducible shRNA targeting PRMT5 with MTAP inhibitor to induce
MTA accumulation and reduce activity of the endogenous
PRMT5 (Figures 4E and S4). We then assessed the impact of
PRMT5 knockdown on the growth of HCT116 MTAPwt cells in
the absence or presence of MTAP inhibitor (Figures 5D and 5E).
Similar to thephenotype observed inMTAP/ cells,MTAP inhib-
itor treatment sensitized MTAPwt cells to PRMT5 knockdown
(Figure 5D).
A potent and selective inhibitor of PRMT5, EPZ015666, was
developed recently (Chan-Penebre et al., 2015). Thus, we sought
to test whether pharmacologic targeting of PRMT5 function
in MTAP-deficient cells would recapitulate our finding using ge-
netic ablation of PRMT5. Surprisingly, growth inhibition upon
pharmacologic inhibition of PRMT5 with EPZ015666 was not
selective for the MTAP/ genetic background (Figure 5F).
EPZ015666 treatment reduced SDMA levels in both MTAP/
andMTAPwt cells, with modestly better potency in theMTAPwt
cells (Figure 5G).We then tested the impact of EPZ015666 on the
growth of a panel of 64 cell lines. Again, we did not observe dif-
ferential sensitivity ofMTAP-deleted cells to growth inhibition by
EPZ015666 (Figure 5H; Table S5), indicating that the lack of se-
lective growth inhibition with EPZ015666 is not unique to the
genetically engineered HCT116 cell model. This finding was
unexpected, considering that the catalytically dead mutant of
PRMT5 did not rescue the growth of PRMT5 shRNA-expressing
HCT116 MTAP/ cells, which suggested that loss of PRMT5
catalytic function was necessary and sufficient for selective
growth inhibition ofMTAP/ cells (Figures 5A–5C). This discrep-
ancy between the impact of genetic and that of pharmacologic
PRMT5 ablation on the growth ofMTAP/ cells led us to assess
the mechanistic link between MAT2A and PRMT5 in MTAP/
cells as a means to validate the synthetic lethal relationships
between MAT2A/PRMT5 and MTAP.
MAT2A Loss Selectively Inhibits PRMT5 Activity in
MTAP-Deleted Cells
MAT2A generates SAM, which is the universal substrate
for cellular methylation reactions; thus, reduction in SAM
levels upon depletion of MAT2A may affect the function ofCell Reports 15, 574–587, April 19, 2016 579
Figure 4. MTA Inhibits PRMT5 Activity
In Vitro and In Vivo
(A) MTA sensitivity of a panel of N-methyl-
transferases. A panel of small molecule-, DNA-,
lysine-, and arginine- N-methyltransferases was
tested using an in vitro assay in the presence of
10 and 100 mM concentrations of MTA.
(B) Dose-response curve for MTA inhibition of
PRMT5 complex activity in an in vitro assay.
(C) Waterfall plot of the MTA Ki values for a subset
of N-methyltransferases. The PRMT5 data point is
highlighted in red.
(D) Immunoblot analysis of the indicated proteins in
a panel ofMTAPwt andMTAP-deleted cancer cell
lines of various tumor origin. HCT116MTAPwt and
MTAP/ cell lines were included as a reference.
Levels of SDMA marks were quantified using
LI-COR software (value ± SD). The p value was
calculated using a two-tailed unpaired t test.
(E) Immunoblot analysis of the indicated proteins in
HCT116 MTAP/ and MTAPwt cells treated with
the MTA transition state analog inhibitor of MTAP
(MTAPi) at 250 or 500 nM for 3 days.methyltransferases, including PRMT5. To that end, we mea-
sured levels of PRMT5-dependent SDMAmarks in our shMAT2A
HCT116 isogenic pair. We observed a significant reduction in
SDMA marks upon MAT2A knockdown in MTAP/ cells but
not MTAPwt cells (Figure 6A). The MTAP/ selective reduction
in PRMT5-dependent SDMA marks upon MAT2A knockdown
was rescued in the presence of shRNA-resistant MAT2A or
MTAP cDNA (Figure S6). We next testedwhether MTAP pharma-
cologic inhibition would similarly synergize with MAT2A knock-
down to reduce SDMAmarks inMTAPwt cells. Much like genetic
deletion ofMTAP, pharmacologic inhibition of MTAP, combined
with MAT2A knockdown, led to a profound reduction in SDMA
marks (Figure 6B). Finally, we confirmed that MAT2A knockdown
reduces SDMA marks in MCF7 cells, which possess an endog-
enous deletion of the CDKN2A/MTAP locus (Figure 6C). In com-
bination with our observation regarding the strong inhibitory
impact of MTA on PRMT5 activity, these data suggest that
PRMT5 function in the MTAP-deleted background is highly
dependent on adequate availability of SAM. PRMT5 was re-
ported in the literature to exhibit low affinity for SAM
(Antonysamy et al., 2012; Sun et al., 2011). We thus compared
SAM Michaelis-Mentin constant (Km) values for the N-methyl-
transferases from our in vitro biochemical panel analysis and580 Cell Reports 15, 574–587, April 19, 2016observed that PRMT5 exhibited the
lowest affinity for SAM (Figure 6D). This
finding may explain PRMT5 dependence
on proper MAT2A function, especially in
the metabolically altered, high-MTA envi-
ronment of MTAP-deficient cells (Fig-
ure 6E). These data demonstrate that
metabolic vulnerability due to MTAP defi-
ciency extends upstream of PRMT5,
creating dependence on the availability
of PRMT5 substrate SAM and therefore
the activity of SAM-producing enzymeMAT2A. In addition, we observed MAT2A sensitivity in a number
of MTAP-deleted cancer cell lines, indicating that this selective
vulnerability is a bona fide feature of cancers with deletion of
chr9p21.
Multiple PRMT5Co-Complexes Are Vulnerable inMTAP-
Deleted Cells
The Rio domain containing protein, RIOK1, was another strong
hit in our shRNA depletion screening campaign. Because it is a
PRMT5 binding partner, we sought to confirm the synthetic lethal
phenotype upon genetic ablation of RIOK1 in the HCT116 MTAP
isogenic cells. Similar to the characterization that was performed
for PRMT5 and MAT2A, inducible RIOK1 shRNA cell lines, as
well as RIOK1wt rescue and RIOK1 active site (D324N) and
ATP binding domain (K208R) catalytically inactive mutant (An-
germayr et al., 2002; Widmann et al., 2012) cell lines, were
created. RIOK1 knockdown and re-expression efficiencies
were evaluated by western blot (Figure 7A). Confirming our
finding in the genomic screen, RIOK1 knockdown resulted in
selective inhibition of the growth of HCT116 MTAP/ cells,
with minimal impact on the growth of MTAPwt cells (Figure 7B).
The growth phenotype was rescued by the expression of
shRNA-resistant WT RIOK1 but not by catalytically inactive
Figure 5. PRMT5 Is Selectively Essential in MTAP/ Cells upon Genetic Ablation but Not Pharmacologic Targeting
(A) Immunoblot analysis of the indicated proteins in the HCT116 isogenic pair stably expressing PRMT5 shRNA and either p-LVX empty vector control,
shRNA-resistant PRMT5wt cDNA, or PRMT5 R368A catalytically dead mutant cDNA.
(B) PRMT5 is selectively essential in MTAP/ cells in vitro. Percent growth of HCT116 MTAP/ and MTAPwt cells upon PRMT5 knockdown (+DOX), with or
without PRMT5wt or R368A mutant rescue, versus no knockdown (DOX) control in a 10-day colony growth assay (mean ± SD, n = 3). The p values were
calculated using a two-tailed paired t test.
(C) Immunoblot analysis of SDMA marks in the HCT116 isogenic pair stably expressing PRMT5 shRNA and either p-LVX empty vector control, shRNA-resistant
PRMT5wt cDNA, or PRMT5 R368A catalytically dead mutant cDNA.
(D) Percent growth of HCT116MTAPwt cells upon PRMT5 knockdown (+DOX) in a 4-day in vitro growth assay. The experiment was performed in parallel in the
absence or presence of the MTA transition state analog inhibitor of MTAP (MTAPi) at 250 nM (mean ± SD, n = 6). The p values were calculated using a two-tailed
paired t test.
(E) Immunoblot analysis of the indicated proteins in HCT116MTAPwt cells stably expressing PRMT5 shRNA upon PRMT5 knockdown (+DOX) or co-treatment
with MTAPi.
(F) Dose-response analysis with EPZ015666 titrated from a 20 mM top dose in HCT116 MTAPwt versus MTAP/ cells (mean ± SD, n = 3).
(G) Immunoblot analysis of PRMT5-dependent SDMA marks in the HCT116 isogenic cell line pair treated with indicated doses of EPZ015666 for 5 days.
(H) Analysis of EPZ015666 sensitivity in a cell line panel. Dose-response curveswere generated for each cell line, and absolute inhibitor concentration 50 (IC50) for
EPZ015666 was determined and used as a measure of sensitivity (20 mM cutoff).K208R/D324N mutant RIOK1 (Figure 7B). To extend this finding
beyond the genetically engineered HCT116 MTAP/ model
system, we performed shRNA-mediated knockdown of RIOK1and PRMT5 in MIAPACA-2 cells, which possess endogenous
deletion of the CDKN2A/MTAP locus. Depletion of RIOK1
or PRMT5 reduced growth of MIAPACA-2 cells (Figure 7C).Cell Reports 15, 574–587, April 19, 2016 581
Figure 6. MAT2A Ablation Selectively In-
hibits PRMT5 Activity in MTAP/ Cells
(A) Immunoblot analysis of the indicated proteins
in the HCT116 isogenic pair stably expressing NT
shRNA (shNT) or shMAT2A.
(B) Immunoblot analysis of the indicated proteins
in the HCT116MTAPwt cell line stably expressing
shNT or shMAT2A in the presence or absence of
MTAP inhibitor (250 nM).
(C) Immunoblot analysis of the indicated proteins
in the MCF7 cells stably expressing shNT,
shMAT2A, and shRNA-resistant MAT2A cDNA
(shMAT2A+resc). For (A)–(C), DOX (200 ng/ml) was
added to induce shMAT2A expression.
(D) SAM Km values (in micromolars) are shown for
a panel of methyltransferases analyzed for their
sensitivity to MTA.
(E) Schematic depicting convergence of MTAP
deficiency-induced metabolic vulnerability due
to MTA accumulation and reduced levels of
SAM uponMAT2A ablation on PRMT5, resulting in
reduced PRMT5 function in a MTAP-deleted,
SAM-deprived environment.Depletion of these target proteins upon induction of shRNA
expression was confirmed by western blot (Figure 7D). These
data demonstrate that the metabolic vulnerability arising upon
accumulation of MTA in an MTAP-deficient background extends
downstream of PRMT5 and affects PRMT5 binding partner
RIOK1.
PRMT5 participates in several multimeric protein co-com-
plexes, including the obligatory binding partner WD45/MEP50
(Wilczek et al., 2011), the mutually exclusive partners pICln and
RIOK1 (Guderian et al., 2011), and the nuclear regulator of spec-
ificity COPR5 (co-operator of PRMT5) (Lacroix et al., 2008).
MEP50, pICln, and COPR5 were not represented in the shRNA
library used in our initial screen (Figures 1B–1F); thus, the screen
did not provide data indicating whether the MTAP synthetic
lethality is shared by other PRMT5 co-complex members or
is unique to RIOK1. To determine whether the vulnerability of
MTAP-deficient cells extends to PRMT5 co-complexes beyond
the RIOK1 co-complex, we performed siRNA pool-mediated
knockdown of multiple PRMT5 co-complex members, including
PRMT5, RIOK1, MEP50, pICln, and COPR5, in the HCT116
isogenic pair (Figures 7E and S7A). We observed selective inhi-
bition of the growth of MTAP-deficient cells upon knockdown582 Cell Reports 15, 574–587, April 19, 2016of each PRMT5 co-complex partner (Fig-
ure 7E). We assessed PRMT5 protein
levels following knockdown of each of
these proteins (Figure S7B) and observed
that MEP50 knockdown led to a reduc-
tion in PRMT5 levels, while knockdown
of RIOK1, pICln, or COPR5 did not.
Thus, reduction in PRMT5 levels second-
ary to knockdown of these proteins is not
sufficient to explain the MTAP-selective
growth inhibition. These data suggest
that vulnerability of MTAP-deficient cells
is not restricted to the RIOK1 co-complexbut rather is broad, affecting several co-complexes involving
PRMT5 as a binding partner. Knockdown of these PRMT5 co-
complex members led to differential effects on SDMA marks,
demonstrating that these proteins constitute different PRMT5
co-complexes (Figure S7C).
DISCUSSION
The mammalian metabolome is characterized by a high degree
of flexibility and redundancy (Thiele et al., 2013). MTA is thus un-
usual in that it is consumed by a solitary, non-redundant enzyme,
MTAP. We observed that upon MTAP deletion, MTA accumu-
lates to an intracellular concentration of approximately 100 mM,
and cells begin to excrete excess MTA. This accumulation of
MTA led to an unexpected collateral vulnerability in the arginine
methyltransferase PRMT5.While the shRNA library contained 39
methyltransferases, PRMT5 was unique in its high degree of
MTAP selectivity. Biochemical profiling of methyltransferases
revealed a molecular basis for this phenomenon. Among the
33 methyltransferases that we tested in vitro, PRMT5 was the
enzyme most sensitive to inhibition by MTA. In vitro inhibition
of PRMT5 by MTA occurs at concentrations similar to those
Figure 7. Multiple PRMT5 Co-complexes Are Vulnerable in MTAP/ Cells
(A) Immunoblot analysis of the indicated proteins in the HCT116 isogenic pair stably expressing RIOK1 shRNA and empty vector control (EV), RIOK1 shRNA
and shRNA-resistant RIOK1wt cDNA (RIOK1wt), or RIOK1 K208R/D324N catalytically dead mutant cDNA. DOX (200 ng/ml) was added to induce shRNA
expression.
(B) Percent growth of HCT116 MTAP/ and MTAPwt cells upon RIOK1 knockdown (+DOX), with or without RIOK1wt or RIOK1 K208R/D324N mutant rescue,
versus no knockdown (DOX) control in a 10-day colony growth assay (mean ± SD, n = 3).
(C) Percent growth of MIAPACA-2 MTAP-deleted cells upon PRMT5 or RIOK1 knockdown (+DOX) in a 10-day colony growth assay (mean ± SD, n = 3).
(D) Immunoblot analysis of the indicated proteins in MIAPACA-2 cells stably expressing PRMT5 or RIOK1 shRNA. DOX (200 ng/ml) was added to induce shRNA
expression.
(E) Percent growth ofMTAP/ andMTAPwt cells upon transfection with NT siRNA or siRNA targeting PRMT5, RIOK1, pICln, MEP50, or COPR5 asmeasured in a
4-day growth assay. (mean ± SD, n = 5). All p values were calculated using a two-tailed paired t test.observed inMTAP-deleted cells, suggesting that this is a biolog-
ically relevant phenomenon. We observed substantially reduced
basal levels of PRMT5methyl marks in cells withMTAP deletion.
Reduced basal PRMT5 activity creates a vulnerability to further
ablation of PRMT5 by shRNA. Consistent with our findings,
large-scale shRNA screening of broad panels of cancer cell lines
has identified the collateral vulnerability to PRMT5 suppression
that arises in cancer cell lines with MTAP deletion (Kryukov
et al., 2016; Mavrakis et al., 2016). These large-scale screeningefforts demonstrate that the collateral vulnerability to PRMT5
persists in many MTAP-null cancer cell lines and thus are com-
plementary with our work in MTAP isogenic cells. In addition,
we show that the collateral vulnerability extends to the upstream
metabolic enzyme MAT2A, as well as to downstream PRMT5
co-complex members such as RIOK1. Thus, these three en-
zymes constitute a vulnerable axis in MTAP-deleted cells.
Treatment with PRMT5 inhibitor EPZ015666 did not lead to
selective growth inhibition in MTAP-deleted cells. There areCell Reports 15, 574–587, April 19, 2016 583
several possible explanations for this disconnect between phar-
macologic inhibition andgenetic knockdownofPRMT5. First, a ki-
netic difference in time required to ablate PRMT5 activity could
lead to a different cellular outcome between small molecule inhib-
itor andshRNA-mediatedknockdown.Second, it ispossible that a
subset of cellular PRMT5 is not accessible to inhibition by
EPZ015666. This could arise if a PRMT5 binding partner were to
occlude the EPZ015666 binding site on PRMT5. Such a phenom-
enon could serve to protect a pool of PRMT5 enzyme molecules.
Lastly, it is possible that the mode of inhibition of PRMT5 by
EPZ015666 negatively affects EPZ015666 inhibition of PRMT5 in
high-MTA settings. EPZ015666 binds selectively to the SAM-
PRMT5complex via acation-pimolecular interaction (Chan-Pene-
bre et al., 2015) that is not possiblewith theMTA-PRMT5complex.
Thus, EPZ015666 cannot bind efficiently to the MTA-PRMT5
complex. Studies with other inhibitor families, such as G-protein
coupled receptors, have noted that two inhibitors of a single
enzyme can only be synergistic if they bind to separate binding
sitesand their interactionwith target isnotmutuallyexclusive (Brei-
tinger, 2012). We predict that EPZ015666 is not synergistic with
MTA and hypothesize that exploiting the PRMT5 vulnerability in
MTAP-deleted cancers may require the development of MTA-se-
lective PRMT5 inhibitors that bind to the MTA-bound form of
PRMT5and trap the enzyme in that state.MTA-selective inhibitors
might afford a greater therapeutic window than that afforded by
non-selective inhibitors, because MTAP expression in normal tis-
sues should provide a protective effect by maintaining low MTA
levels. Mouse genetic studies have revealed that PRMT5 has
important roles in normal physiology; PRMT5 knockout leads to
embryonic lethality (Tee et al., 2010), and substantial toxicities
arise upon tissue-specific PRMT5 knockout in the CNS (Bezzi
et al., 2013), skeletal muscle (Zhang et al., 2015), and hematopoi-
etic lineages (Liu et al., 2015). These toxicities may become dose
limiting in the clinical setting, narrowing the therapeutic potential
of agents that non-selectively target PRMT5.
Cellular methyltransferase activity is subject to regulatory
control by small molecule metabolites. It has previously been
established that methyltransferases are regulated by the rela-
tive balance of substrate SAM and product S-adenosylhomo-
cysteine (SAH) (Vance et al., 1997). The SAM/SAH ratio is
used to calculate cellular ‘‘methylation potential’’ as a measure
of cellular poise to conduct methyltransferase reactions (Wil-
liams and Schalinske, 2007). Our observation that PRMT5
can be inhibited by MTA implicates PRMT5 as the exemplar
member of a biochemically distinct family of methyltransferases
that can be regulated by the SAM/MTA ratio. This regulatory
mode is revealed clearly in MTAP-deleted cancer cells, where
MTA levels accumulate dramatically. Limited information is
available regarding MTA levels across normal tissues (Stevens
et al., 2010), and wider MTA screening might reveal other set-
tings in which MTA accumulation leads to inhibition of PRMT5.
In addition, PRMT5 has a fairly weak binding affinity for SAM.
This is unusual among the methyltransferase family, because
most mammalian methyltransferases have SAM Km values
10- to 100-fold below its physiologic concentration (Richon
et al., 2011). This biochemical finding implies that PRMT5
is poised as a SAM-sensitive methyltransferase, and this
sensitivity is exemplified by the reduction in PRMT5 methyl584 Cell Reports 15, 574–587, April 19, 2016marks that is observed upon MAT2A depletion in MTAP-
deleted cells.
PRMT5 activity may be mechanistically connected to MAT2A
activity through both the relatively poor affinity of PRMT5 for
SAMand its high affinity forMTA, as well as the SAM-competitive
natureofMTA-mediated inhibition. In cellswith activeMTAP,MTA
concentrations are low, and the ratio of the cellular concentration
of SAM in comparison to the Km for SAM is higher than the ratio of
the concentration ofMTA to the Ki forMTA; the PRMT5 enzyme is
active as thePRMT5:SAMform is favored (Figure 6E). In themeta-
bolically altered, high-MTA environment of MTAP-deficient cells,
the ratio of the cellular concentration of MTA to the Ki for MTA is
increasedcompared toWTcells; PRMT5activity ismore sensitive
to decreases in the cellular concentration of SAM. Reduction in
SAM concentration due to knockdown of the SAM-producing
MAT2A enzyme further tilts the equilibrium between the active
PRMT5:SAM and the inactive PRMT5:MTA complexes toward
the inactive form, resulting in a global decrease in PRMT5 activity.
PRMT5 regulates a number of proliferative and biosynthetic
processes, such as histone methylation that controls expression
of cell-cycle genes (Chung et al., 2013), methylation of growth
factor signaling components like EGFR and Raf (Andreu-Pe´rez
et al., 2011; Hsu et al., 2011), and methylation of key protein
components required for maturation of ribosome and spliceo-
some complexes (Friesen et al., 2001; Ren et al., 2010). Thus,
PRMT5 activity leads to coordinated upregulation of a range of
pro-proliferative and biosynthetic pathways. PRMT5 has been
demonstrated to be important for proliferation in tumor models
in vivo (Gu et al., 2012; Yan et al., 2014). The tumor models
used in these studies happen to carry endogenous deletion of
the CDKN2A/MTAP locus. PRMT5 is an attractive therapeutic
target, and our work suggests that inhibitors that could trap
PRMT5 in the MTA-bound state may have particularly robust
therapeutic window in CDKN2A/MTAP-deleted tumors.
The vulnerability of PRMT5 in MTAP-deficient cancers ex-
tends both upstream of PRMT5 (to MAT2A) and downstream
of PRMT5 (to RIOK1 and other PRMT5 co-complex members).
Thus, in addition to the potential to devise MTA-selective
PRMT5 inhibitors, our work demonstrates that therapeutic tar-
geting of MAT2A, RIOK1, or other PRMT5 co-complex members
could selectively affect MTAP-deleted cancers while sparing
MTAP-expressing normal tissues. Using catalytically dead point
mutants of RIOK1, we demonstrate that catalytic activity of the
enzyme is critical, indicating that pharmacologic inhibitors of
RIOK1 may selectively block growth of MTAP-deficient cancers.
Thus, this vulnerable axis merits further consideration for thera-
peutic targeting to address the unmet clinical need in 15% of
human cancers with deletion of the CDKN2A/MTAP locus.
In addition, these collateral vulnerabilities of MTAP-deficient
cancers exemplify an extensible approach to target tumor
suppressor loss of function by identification of synthetic lethal
relationships with co-deleted metabolic genes.EXPERIMENTAL PROCEDURES
Cell Lines
HCT116 colon carcinomaMTAPwt cells and theMTAP/ isogenic clone were
licensed from Horizon Discovery. All other cell lines were obtained from the
American Type Culture Collection, RIKEN Bioresource Center cell bank, or
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ).
shRNA-Based Genomic Screen
See Supplemental Experimental Procedures for a detailed description of
the shRNA screen and data analysis.
Generation of Stable Inducible shRNA and cDNA Rescue Cell Lines
All shRNAs constructs were cloned into the pLKO-Tet-on lentiviral backbone
vector (Wiederschain et al., 2009) or pSLIK-Tet-on vector. MTAP, PRMT5,
MAT2A, RIOK1 WT, and catalytically dead mutant cDNAs were cloned into
pLVX-IRES-neo/puro/blast lentiviral vector. See Supplemental Experimental
Procedures for shRNA sequences and additional details.
siRNA Transfections
Cells were transfected with ON-Target plus SMARTpool siRNAs (Dharmacon)
using Lipofectamine RNAiMAX (13778-150, Life Technologies) per vendor pro-
tocol. To ensure robust and durable knockdown of the target, two sequential
transfections were performed, separated by 24 hr of recovery in full growth
media (RPMI + 10% fetal bovine serum). At 24 hr after the second transfection,
cells were trypsinized, counted, and plated for 96-well format growth assays.
Growth Assays
Following siRNA transfection or 4-day pre-treatment with 200 ng/ml DOX as
relevant, cells were plated in 96-well tissue culture plates at 1,000 to 3,000
cells per well. CellTiter-Glo ATP assay (Promega) was performed on parallel
assay plates at t0 and at the end of the cell culture period as indicated in figure
legends. Percent growth was calculated as either percent change in the lumi-
nescence readout for the experimental condition at the end of the assay,
compared to that of NT hairpin control in the absence of DOX, or as percent
change in the tend/t0 luminescence readout normalized to that of NT or Luc
hairpin control in the presence of DOX.
For colony formation assays, cells were plated at 1,000 per well in a 6-well
plate and DOX treatment (200 ng/ml) was initiated at the time of plating using
an equivalent volume of sterile water as vehicle control. Colonies were fixed
after 10 days and stained with 0.05% crystal violet in 4.5% paraformaldehyde
solution for 24 hr. Colonies were quantified using LI-COR image processing
software (LI-COR Biosciences).
Immunoblotting
Antibodies used in immunoblotting are listed in Supplemental Experimental
Procedures.
PRMT5 Inhibitor
PRMT5 inhibitor EPZ015666 was synthesized following the published syn-
thetic protocol (Chan-Penebre et al., 2015).
N-Methyltransferase In Vitro Activity Assays
In vitro screening of methyltransferase inhibition by MTA, as well as SAM Km
measurements, was conducted using a panel of standard methyltransferase
assays at Eurofins CEREP Panlabs. Additional information regarding assay
methods and in vitro assay data analysis can be found in Supplemental Exper-
imental Procedures.
Metabolite Extraction and LC-MS Analysis
For media analysis, conditioned media were collected from cells that were
cultured for at least 24 hr and diluted 20-fold before LC-MS analysis. For intra-
cellular metabolites, organic extraction was performed with cold 80%/20%
(v/v) methanol/water with d8-putrescine added as an internal standard
following normalization to cell number. Samples were then dried under
reduced pressure and stored at 80C until LC-MS analysis. See Supple-
mental Experimental Procedures for additional details regarding sample pro-
cessing, LC-MS, and data analysis.
Xenograft Studies
See Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.03.043.
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